User:Doc James/sandbox3

Summary
Trifluoperazine is an effective antipsychotic for people with schizophrenia but it increases the risk of extrapyramidal adverse effects.
Outcome Findings in words Findings in numbers Quality of evidence Global state Clinical improvement Follow-up: average 19 weeks Trifluoperazine increases the chance of being 'improved' when compared to placebo. Data are based on low quality evidence. RR 4.61 (1.54 to 13.84) Low Relapse or worsening Follow-up: average 5 months Trifluoperazine reduces the risk of relapse when compared with placebo. Data are based on low quality evidence. RR 0.34 (0.23 to 0.49) Low Mental state Experiencing 'intensified symptoms' Follow-up: average 16 weeks At present it is not possible to be confident about the difference between trifluoperazine and placebo for this outcome and data supporting this finding are very limited. RR 1.05 (0.54 to 2.05) Very low Leaving the study early - Because of any reason Follow-up: average 5 months Trifluoperazine may reduce loss to follow-up, but, at present it is not possible to be confident about the difference between the two treatments and data supporting this finding are very limited. RR 0.67 (0.38 to 1.19) Very low - Because of severe adverse effects Follow-up: average 2 months It is not possible to be confident about the difference between trifluoperazine and placebo. Data supporting this finding are very limited. RR 1.31 (0.22 to 7.8) Very low Behavior Any clinically significant agitation or distress Follow-up: 4 months There was no clear differences between trifluoperazine and placebo for this outcome. Data supporting this finding are very limited. RR 2.0 (0.19 to 20.72) Very low Economic outcomes No included randomized study reported on economic outcomes.